Decisions 16th January 2018

At the meeting on the 16th January the following decisions were agreed

New Drug Requests


Trelegy Ellipta Inhaler (Fluticasone/umeclidinium/vilanterol) (TLS green)

  • Approved for inclusion onto the formulary for maintenance treatment of COPD patients.

Not Approved

Saxenda (Liraglutide)

  •  Not approved for inclusion onto the formulary for weight management in patients with obesity.

Shared Care Protocols/TLS change in Status

Ciclosporin Eye drops

  • TLS change from red to amber. Shared care protocol agreed.

Leflunomide (rheumatology)

  • Shared care protocol updated.

Sulfasalazine  (rheumatology)

  • Shared care protocol updated.


  • Monitoring responsibilities still being clarified. To be uploaded onto webite when agreed.


  • Shared care protocol updated to include preferred brands.


  • Agreed change from TLS amber 1 month to amber no SCP to facilitate timely prescribing by GPs when needed urgently. Shared care protocol to be adapted into prescribing guidance for GPs.

Sodium Valproate/Semi-sodium valproate

  • Existing shared care protocol updated to include sodium valproate as preferred first line choice for bipolar disorder and to include clearer MHRA warnings regarding pregnancy.

Last updated by: Emily Knight on 05-02-2018 15:35